Donor choice according to age for allo-SCT for AML in complete remission

F Ayuk; T Zabelina; F Wortmann; H Alchalby; C Wolschke; H Lellek; U Bacher; Axel R. Zander; Nicolaus Kröger

doi:10.1038/bmt.2013.14

Donor choice according to age for allo-SCT for AML in complete remission

F Ayuk, T Zabelina, F Wortmann, H Alchalby, C Wolschke, H Lellek, U Bacher, Axel R. Zander, Nicolaus Kröger

Clinic of Internal Medicine I

University Hospital Hamburg-Eppendorf

Abstract

In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

Original language	English
Journal	Bone Marrow Transplantation
Volume	48
Issue number	8
Pages (from-to)	1028-32
Number of pages	5
ISSN	0268-3369
DOIs	https://doi.org/10.1038/bmt.2013.14
Publication status	Published - 08.2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bmt.2013.14

Cite this

@article{536b1ef5608c4f25894f2418c9d0bdc0,

title = "Donor choice according to age for allo-SCT for AML in complete remission",

abstract = "In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.",

author = "F Ayuk and T Zabelina and F Wortmann and H Alchalby and C Wolschke and H Lellek and U Bacher and Zander, {Axel R.} and Nicolaus Kr{\"o}ger",

year = "2013",

month = aug,

doi = "10.1038/bmt.2013.14",

language = "English",

volume = "48",

pages = "1028--32",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

number = "8",

}

TY - JOUR

T1 - Donor choice according to age for allo-SCT for AML in complete remission

AU - Ayuk, F

AU - Zabelina, T

AU - Wortmann, F

AU - Alchalby, H

AU - Wolschke, C

AU - Lellek, H

AU - Bacher, U

AU - Zander, Axel R.

AU - Kröger, Nicolaus

PY - 2013/8

Y1 - 2013/8

N2 - In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

AB - In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

U2 - 10.1038/bmt.2013.14

DO - 10.1038/bmt.2013.14

M3 - Journal articles

C2 - 23419435

SN - 0268-3369

VL - 48

SP - 1028

EP - 1032

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 8

ER -

Donor choice according to age for allo-SCT for AML in complete remission

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this